No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients

BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week tre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Gastroenterol Hepatol
Main Authors: Marcus, Julia L., Hurley, Leo B., Chamberland, Scott, Champsi, Jamila H., Gittleman, Laura C., Korn, Daniel G., Lai, Jennifer B., Lam, Jennifer O., Pauly, Mary Patricia, Quesenberry, Charles P., Ready, Joanna, Saxena, Varun, Seo, Suk, Witt, David J., Silverberg, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5962408/
https://ncbi.nlm.nih.gov/pubmed/29535057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.03.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados